"In 2011, in the course of the pilot data collection coordinated by the National Centre for Addictions, 9 service providers reported clients participating in methadone or buprenorphine-naloxone treatment (out of the 12 service providers providing such treatments in the country). On the basis of the service providers? reports a total number of 715 clients received methadone or buprenorphine-naloxone treatment during the year. This value indicates a 31% drop as compared to the 1031 cases reported in the previous year, and this is due to the coverage of data collection and to the measures to control double counting58. In summary the quality of the data improved, but coverage slightly decreased (from about 98% to 90% of the cases).
"In 2011 9.9% of the clients receiving methadone or buprenorphine-naloxone treatment (70 persons) received their substitution drug for the purpose of detoxification, 90.1% (639 persons) in the scope of substitution treatment59. In respect of the substitution drug, 79.8% of the clients participating in substitution treatment (510 persons) were prescribed methadone, while 20.2% (129 persons) were prescribed buprenorphine-naloxone. In the case of detoxification treatments the use of buprenorphine-naloxone was more typical (in 46 cases, 65%)."


Drog Focuszpont, "HUNGARY: 2012 National Report to the EMCDDA by the Reitox National Focal Point - New Development, Trends and in-depth information on selected issues" (Budapest, Hungary: Drog Focuszpont 2012), pp. 43-44.